<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalents" xlink:label="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalents_1"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalents" xlink:label="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalents_2"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromContinuingAndDiscontinuedOperations" xlink:label="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromContinuingAndDiscontinuedOperations_3"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromContinuingAndDiscontinuedOperations" xlink:label="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromContinuingAndDiscontinuedOperations_4"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromDiscontinuedOperations" xlink:label="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromDiscontinuedOperations_5"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromDiscontinuedOperations" xlink:label="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromDiscontinuedOperations_6"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsIfDifferentFromTheStatementOfFinancialPosition" xlink:label="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsIfDifferentFromTheStatementOfFinancialPosition_7"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsIfDifferentFromTheStatementOfFinancialPosition" xlink:label="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsIfDifferentFromTheStatementOfFinancialPosition_8"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_DisclosureOfDistributionExpenses" xlink:label="loc_lavipharm_DisclosureOfDistributionExpenses_9"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_DisclosureOfDistributionExpenses" xlink:label="loc_lavipharm_DisclosureOfDistributionExpenses_10"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_GainLossFromDerecognitionOfSubsidiaries" xlink:label="loc_lavipharm_GainLossFromDerecognitionOfSubsidiaries_11"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_GainLossFromDerecognitionOfSubsidiaries" xlink:label="loc_lavipharm_GainLossFromDerecognitionOfSubsidiaries_12"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_OtherTransactionsBetweenEquity" xlink:label="loc_lavipharm_OtherTransactionsBetweenEquity_13"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_OtherTransactionsBetweenEquity" xlink:label="loc_lavipharm_OtherTransactionsBetweenEquity_14"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_PaymentsTowardsBorrowingsClassifiedAsFinancingActivitiesGreekState" xlink:label="loc_lavipharm_PaymentsTowardsBorrowingsClassifiedAsFinancingActivitiesGreekState_15"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_PaymentsTowardsBorrowingsClassifiedAsFinancingActivitiesGreekState" xlink:label="loc_lavipharm_PaymentsTowardsBorrowingsClassifiedAsFinancingActivitiesGreekState_16"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_ProceedsFromBorrowingsClassifiedAsFinancingActivitiesGreekState" xlink:label="loc_lavipharm_ProceedsFromBorrowingsClassifiedAsFinancingActivitiesGreekState_17"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_ProceedsFromBorrowingsClassifiedAsFinancingActivitiesGreekState" xlink:label="loc_lavipharm_ProceedsFromBorrowingsClassifiedAsFinancingActivitiesGreekState_18"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_ProceedsFromSaleAndLeasebackOfTangibleAssets" xlink:label="loc_lavipharm_ProceedsFromSaleAndLeasebackOfTangibleAssets_19"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_ProceedsFromSaleAndLeasebackOfTangibleAssets" xlink:label="loc_lavipharm_ProceedsFromSaleAndLeasebackOfTangibleAssets_20"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_ProfitLossBeforeTaxContinuingOperations" xlink:label="loc_lavipharm_ProfitLossBeforeTaxContinuingOperations_21"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_ProfitLossBeforeTaxContinuingOperations" xlink:label="loc_lavipharm_ProfitLossBeforeTaxContinuingOperations_22"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_ValuationGreekGovernmentBonds" xlink:label="loc_lavipharm_ValuationGreekGovernmentBonds_23"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_ValuationGreekGovernmentBonds" xlink:label="loc_lavipharm_ValuationGreekGovernmentBonds_24"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalents_0" xml:lang="en">Ταμειακά διαθέσιμα και ταμειακά ισοδύναμα και ταμειακά διαθέσιμα και ταμειακά ισοδύναμα με περιορισμό</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalents_4" xml:lang="en">Cash And Cash Equivalents And Restricted Cash And Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromContinuingAndDiscontinuedOperations_0" xml:lang="en">Ταμειακά διαθέσιμα και ισοδύναμα και ταμειακά διαθέσιμα και ισοδύναμα με περιορισμό συνεχιζόμενων &amp; διακοπεισών δραστηριοτήτων</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromContinuingAndDiscontinuedOperations_2" xml:lang="en">Cash And Cash Equivalents And Restricted Cash And Cash Equivalents From Continuing And Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromDiscontinuedOperations_0" xml:lang="en">Ταμειακά διαθέσιμα και ισοδύναμα και ταμειακά διαθέσιμα και ισοδύναμα με περιορισμό διακοπεισών δραστηριοτήτων</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromDiscontinuedOperations_3" xml:lang="en">Cash And Cash Equivalents And Restricted Cash And Cash Equivalents From Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsIfDifferentFromTheStatementOfFinancialPosition_1" xml:lang="en">Cash and cash equivalents and restricted cash and cash equivalents if different from the statement of financial position</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsIfDifferentFromTheStatementOfFinancialPosition_4" xml:lang="en">Cash And Cash Equivalents And Restricted Cash And Cash Equivalents If Different From The Statement Of Financial Position</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_lavipharm_DisclosureOfDistributionExpenses_0" xml:lang="en">Η γνωστοποίηση των εξόδων διάθεσης.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_lavipharm_DisclosureOfDistributionExpenses_2" xml:lang="en">Disclosure Of Distribution Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_lavipharm_GainLossFromDerecognitionOfSubsidiaries_0" xml:lang="en">Κέρδη απο εκκαθάριση Θυγατρικής</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_lavipharm_GainLossFromDerecognitionOfSubsidiaries_2" xml:lang="en">Gain Loss From Derecognition Of Subsidiaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_lavipharm_OtherTransactionsBetweenEquity_1" xml:lang="en">Other transactions between equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_lavipharm_OtherTransactionsBetweenEquity_3" xml:lang="en">Other Transactions Between Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_lavipharm_PaymentsTowardsBorrowingsClassifiedAsFinancingActivitiesGreekState_0" xml:lang="en">Πληρωμές έναντι δανείων που ταξινομούνται ως χρηματοδοτικές δραστηριότητες (Ελληνικό Δημόσιο)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_lavipharm_PaymentsTowardsBorrowingsClassifiedAsFinancingActivitiesGreekState_2" xml:lang="en">Payments Towards Borrowings Classified As Financing Activities Greek State</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_lavipharm_ProceedsFromBorrowingsClassifiedAsFinancingActivitiesGreekState_0" xml:lang="en">Εισπράξεις από δανεισμό που ταξινομούνται ως χρηματοδοτικές δραστηριότητες (Ελληνικό Δημόσιο)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_lavipharm_ProceedsFromBorrowingsClassifiedAsFinancingActivitiesGreekState_2" xml:lang="en">Proceeds From Borrowings Classified As Financing Activities Greek State</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_lavipharm_ProceedsFromSaleAndLeasebackOfTangibleAssets_1" xml:lang="en">Proceeds from sale and leaseback of tangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_lavipharm_ProceedsFromSaleAndLeasebackOfTangibleAssets_3" xml:lang="en">Proceeds From Sale And Leaseback Of Tangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_lavipharm_ProfitLossBeforeTaxContinuingOperations_0" xml:lang="en">Κέρδη / Ζημίες προ φόρων, συνεχιζόμενες δραστηριότητες</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_lavipharm_ProfitLossBeforeTaxContinuingOperations_2" xml:lang="en">Profit Loss Before Tax Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_lavipharm_ValuationGreekGovernmentBonds_0" xml:lang="en">Αποτίμηση Ομολόγων Ελληνικού Δημοσίου</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_lavipharm_ValuationGreekGovernmentBonds_2" xml:lang="en">Valuation Greek Government Bonds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalents_1" xlink:to="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalents_2" xlink:to="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalents_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromContinuingAndDiscontinuedOperations_3" xlink:to="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromContinuingAndDiscontinuedOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromContinuingAndDiscontinuedOperations_4" xlink:to="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromContinuingAndDiscontinuedOperations_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromDiscontinuedOperations_5" xlink:to="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromDiscontinuedOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromDiscontinuedOperations_6" xlink:to="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromDiscontinuedOperations_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsIfDifferentFromTheStatementOfFinancialPosition_7" xlink:to="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsIfDifferentFromTheStatementOfFinancialPosition_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsIfDifferentFromTheStatementOfFinancialPosition_8" xlink:to="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsIfDifferentFromTheStatementOfFinancialPosition_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_DisclosureOfDistributionExpenses_9" xlink:to="lab_lavipharm_DisclosureOfDistributionExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_DisclosureOfDistributionExpenses_10" xlink:to="lab_lavipharm_DisclosureOfDistributionExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_GainLossFromDerecognitionOfSubsidiaries_11" xlink:to="lab_lavipharm_GainLossFromDerecognitionOfSubsidiaries_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_GainLossFromDerecognitionOfSubsidiaries_12" xlink:to="lab_lavipharm_GainLossFromDerecognitionOfSubsidiaries_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_OtherTransactionsBetweenEquity_13" xlink:to="lab_lavipharm_OtherTransactionsBetweenEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_OtherTransactionsBetweenEquity_14" xlink:to="lab_lavipharm_OtherTransactionsBetweenEquity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_PaymentsTowardsBorrowingsClassifiedAsFinancingActivitiesGreekState_15" xlink:to="lab_lavipharm_PaymentsTowardsBorrowingsClassifiedAsFinancingActivitiesGreekState_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_PaymentsTowardsBorrowingsClassifiedAsFinancingActivitiesGreekState_16" xlink:to="lab_lavipharm_PaymentsTowardsBorrowingsClassifiedAsFinancingActivitiesGreekState_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_ProceedsFromBorrowingsClassifiedAsFinancingActivitiesGreekState_17" xlink:to="lab_lavipharm_ProceedsFromBorrowingsClassifiedAsFinancingActivitiesGreekState_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_ProceedsFromBorrowingsClassifiedAsFinancingActivitiesGreekState_18" xlink:to="lab_lavipharm_ProceedsFromBorrowingsClassifiedAsFinancingActivitiesGreekState_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_ProceedsFromSaleAndLeasebackOfTangibleAssets_19" xlink:to="lab_lavipharm_ProceedsFromSaleAndLeasebackOfTangibleAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_ProceedsFromSaleAndLeasebackOfTangibleAssets_20" xlink:to="lab_lavipharm_ProceedsFromSaleAndLeasebackOfTangibleAssets_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_ProfitLossBeforeTaxContinuingOperations_21" xlink:to="lab_lavipharm_ProfitLossBeforeTaxContinuingOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_ProfitLossBeforeTaxContinuingOperations_22" xlink:to="lab_lavipharm_ProfitLossBeforeTaxContinuingOperations_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_ValuationGreekGovernmentBonds_23" xlink:to="lab_lavipharm_ValuationGreekGovernmentBonds_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_ValuationGreekGovernmentBonds_24" xlink:to="lab_lavipharm_ValuationGreekGovernmentBonds_2"/>
  </labelLink>
</linkbase>